Clinical trials have also focused on administration of anti-PD-1, which has shown only modest effects in ovarian cancer patients; a recent trial assessing response to anti-PD-L1 in ovarian cancer obtained a 9.7% response rate and 44% stable disease rate amongst patients with platinum-resistant disease (clinical trial NCT01772004) [64]. This evidence concerns the gene PDCD1 and ovarian cancer.